Hyperhomocysteinemia and vitamin B6 deficiency: New risk markers for nonvalvular atrial fibrillation?

Rossella Marcucci, Irene Betti, Emanuele Cecchi, Daniela Poli, Betti Giusti, Sandra Fedi, Ilaria Lapini, Rosanna Abbate, Gian Franco Gensini, Domenico Prisco

Research output: Contribution to journalArticle

Abstract

Background A recent "ex-vivo" study showed that nonvalvular atrial fibrillation (NVAF) is associated with enhanced activity of metalloproteinases at the atrial level, and in animal models homocysteine (Hcy) is able to activate metalloproteinases. The aim of this case-control study was to investigate the association of total Hcy plasma levels, vitamin status (folate, vitamin B6, and vitamin B12), and methylenetetrahydrofolate reductase C677T and CBS 844ins68 polymorphisms with NVAF. Furthermore, the role of these variables in the occurrence of ischemic events was investigated. Methods We studied 310 NVAF patients on oral anticoagulant treatment (168 patients with previous ischemic events and 142 without) and 310 controls. Results Hyperhomocysteinemia (highest quartile) and vitamin B6 deficiency (lowest quartile) were independently associated with NVAF after multivariate analysis (Hcy: odds ratio [OR] 6.40, 95% CI 3.29-12.46; vitamin B6: OR 3.02, 95% CI 1.02-8.95). A significant correlation was found between Hcy levels and left atrial diameter (r = 0.46; P <.001). As shown by multivariate analysis, elevated Hcy levels were an independent risk factor for ischemic complications during NVAF (OR 2.66, 95% CI 1.15-6.20). Conclusions This study demonstrates a significant association of both elevated Hcy levels and low vitamin B6 levels with the presence of NVAF; in addition, it confirms the role of Hcy as a risk factor for ischemic events during NVAF.

Original languageEnglish
Pages (from-to)456-461
Number of pages6
JournalAmerican Heart Journal
Volume148
Issue number3
DOIs
Publication statusPublished - Sep 2004

Fingerprint

Vitamin B 6 Deficiency
Hyperhomocysteinemia
Homocysteine
Atrial Fibrillation
Vitamin B 6
Odds Ratio
Metalloproteases
Multivariate Analysis
Methylenetetrahydrofolate Reductase (NADPH2)
Vitamin B 12
Folic Acid
Vitamins
Anticoagulants
Case-Control Studies
Animal Models

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Marcucci, R., Betti, I., Cecchi, E., Poli, D., Giusti, B., Fedi, S., ... Prisco, D. (2004). Hyperhomocysteinemia and vitamin B6 deficiency: New risk markers for nonvalvular atrial fibrillation? American Heart Journal, 148(3), 456-461. https://doi.org/10.1016/j.ahj.2004.03.017

Hyperhomocysteinemia and vitamin B6 deficiency : New risk markers for nonvalvular atrial fibrillation? / Marcucci, Rossella; Betti, Irene; Cecchi, Emanuele; Poli, Daniela; Giusti, Betti; Fedi, Sandra; Lapini, Ilaria; Abbate, Rosanna; Gensini, Gian Franco; Prisco, Domenico.

In: American Heart Journal, Vol. 148, No. 3, 09.2004, p. 456-461.

Research output: Contribution to journalArticle

Marcucci, R, Betti, I, Cecchi, E, Poli, D, Giusti, B, Fedi, S, Lapini, I, Abbate, R, Gensini, GF & Prisco, D 2004, 'Hyperhomocysteinemia and vitamin B6 deficiency: New risk markers for nonvalvular atrial fibrillation?', American Heart Journal, vol. 148, no. 3, pp. 456-461. https://doi.org/10.1016/j.ahj.2004.03.017
Marcucci, Rossella ; Betti, Irene ; Cecchi, Emanuele ; Poli, Daniela ; Giusti, Betti ; Fedi, Sandra ; Lapini, Ilaria ; Abbate, Rosanna ; Gensini, Gian Franco ; Prisco, Domenico. / Hyperhomocysteinemia and vitamin B6 deficiency : New risk markers for nonvalvular atrial fibrillation?. In: American Heart Journal. 2004 ; Vol. 148, No. 3. pp. 456-461.
@article{ac67bd91c8f24f4e8d93e2fe46051ecf,
title = "Hyperhomocysteinemia and vitamin B6 deficiency: New risk markers for nonvalvular atrial fibrillation?",
abstract = "Background A recent {"}ex-vivo{"} study showed that nonvalvular atrial fibrillation (NVAF) is associated with enhanced activity of metalloproteinases at the atrial level, and in animal models homocysteine (Hcy) is able to activate metalloproteinases. The aim of this case-control study was to investigate the association of total Hcy plasma levels, vitamin status (folate, vitamin B6, and vitamin B12), and methylenetetrahydrofolate reductase C677T and CBS 844ins68 polymorphisms with NVAF. Furthermore, the role of these variables in the occurrence of ischemic events was investigated. Methods We studied 310 NVAF patients on oral anticoagulant treatment (168 patients with previous ischemic events and 142 without) and 310 controls. Results Hyperhomocysteinemia (highest quartile) and vitamin B6 deficiency (lowest quartile) were independently associated with NVAF after multivariate analysis (Hcy: odds ratio [OR] 6.40, 95{\%} CI 3.29-12.46; vitamin B6: OR 3.02, 95{\%} CI 1.02-8.95). A significant correlation was found between Hcy levels and left atrial diameter (r = 0.46; P <.001). As shown by multivariate analysis, elevated Hcy levels were an independent risk factor for ischemic complications during NVAF (OR 2.66, 95{\%} CI 1.15-6.20). Conclusions This study demonstrates a significant association of both elevated Hcy levels and low vitamin B6 levels with the presence of NVAF; in addition, it confirms the role of Hcy as a risk factor for ischemic events during NVAF.",
author = "Rossella Marcucci and Irene Betti and Emanuele Cecchi and Daniela Poli and Betti Giusti and Sandra Fedi and Ilaria Lapini and Rosanna Abbate and Gensini, {Gian Franco} and Domenico Prisco",
year = "2004",
month = "9",
doi = "10.1016/j.ahj.2004.03.017",
language = "English",
volume = "148",
pages = "456--461",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Hyperhomocysteinemia and vitamin B6 deficiency

T2 - New risk markers for nonvalvular atrial fibrillation?

AU - Marcucci, Rossella

AU - Betti, Irene

AU - Cecchi, Emanuele

AU - Poli, Daniela

AU - Giusti, Betti

AU - Fedi, Sandra

AU - Lapini, Ilaria

AU - Abbate, Rosanna

AU - Gensini, Gian Franco

AU - Prisco, Domenico

PY - 2004/9

Y1 - 2004/9

N2 - Background A recent "ex-vivo" study showed that nonvalvular atrial fibrillation (NVAF) is associated with enhanced activity of metalloproteinases at the atrial level, and in animal models homocysteine (Hcy) is able to activate metalloproteinases. The aim of this case-control study was to investigate the association of total Hcy plasma levels, vitamin status (folate, vitamin B6, and vitamin B12), and methylenetetrahydrofolate reductase C677T and CBS 844ins68 polymorphisms with NVAF. Furthermore, the role of these variables in the occurrence of ischemic events was investigated. Methods We studied 310 NVAF patients on oral anticoagulant treatment (168 patients with previous ischemic events and 142 without) and 310 controls. Results Hyperhomocysteinemia (highest quartile) and vitamin B6 deficiency (lowest quartile) were independently associated with NVAF after multivariate analysis (Hcy: odds ratio [OR] 6.40, 95% CI 3.29-12.46; vitamin B6: OR 3.02, 95% CI 1.02-8.95). A significant correlation was found between Hcy levels and left atrial diameter (r = 0.46; P <.001). As shown by multivariate analysis, elevated Hcy levels were an independent risk factor for ischemic complications during NVAF (OR 2.66, 95% CI 1.15-6.20). Conclusions This study demonstrates a significant association of both elevated Hcy levels and low vitamin B6 levels with the presence of NVAF; in addition, it confirms the role of Hcy as a risk factor for ischemic events during NVAF.

AB - Background A recent "ex-vivo" study showed that nonvalvular atrial fibrillation (NVAF) is associated with enhanced activity of metalloproteinases at the atrial level, and in animal models homocysteine (Hcy) is able to activate metalloproteinases. The aim of this case-control study was to investigate the association of total Hcy plasma levels, vitamin status (folate, vitamin B6, and vitamin B12), and methylenetetrahydrofolate reductase C677T and CBS 844ins68 polymorphisms with NVAF. Furthermore, the role of these variables in the occurrence of ischemic events was investigated. Methods We studied 310 NVAF patients on oral anticoagulant treatment (168 patients with previous ischemic events and 142 without) and 310 controls. Results Hyperhomocysteinemia (highest quartile) and vitamin B6 deficiency (lowest quartile) were independently associated with NVAF after multivariate analysis (Hcy: odds ratio [OR] 6.40, 95% CI 3.29-12.46; vitamin B6: OR 3.02, 95% CI 1.02-8.95). A significant correlation was found between Hcy levels and left atrial diameter (r = 0.46; P <.001). As shown by multivariate analysis, elevated Hcy levels were an independent risk factor for ischemic complications during NVAF (OR 2.66, 95% CI 1.15-6.20). Conclusions This study demonstrates a significant association of both elevated Hcy levels and low vitamin B6 levels with the presence of NVAF; in addition, it confirms the role of Hcy as a risk factor for ischemic events during NVAF.

UR - http://www.scopus.com/inward/record.url?scp=4644335244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644335244&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2004.03.017

DO - 10.1016/j.ahj.2004.03.017

M3 - Article

C2 - 15389232

AN - SCOPUS:4644335244

VL - 148

SP - 456

EP - 461

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 3

ER -